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Abstract
Introduction: This prospective, randomized, controlled, experimental animal study looks at the effects of
recombinant human activated protein C (rhAPC) on global hemodynamics and microcirculation in ovine acute
lung injury (ALI) and septic shock, resulting from smoke inhalation injury.
Methods: Twenty-one sheep (37 ± 2 kg) were operatively prepared for chronic study and randomly allocated to
either the sham, control, or rhAPC group (n = 7 each). The control and rhAPC groups were subjected to
insufflation of four sets of 12 breaths of cotton smoke followed by instillation of live Pseudomonas aeruginosa into
both lung lobes, according to an established protocol. Healthy sham animals were not subjected to the injury and
received only four sets of 12 breaths of room air and instillation of the vehicle (normal saline). rhAPC (24 μg/kg/
hour) was intravenously administered from 1 hour post injury until the end of the 24-hour experiment. Regional
microvascular blood flow was analyzed using colored microspheres. All sheep were mechanically ventilated with
100% oxygen, and fluid resuscitated with lactated Ringer’s solution to maintain hematocrit at baseline levels.
Results: The rhAPC-associated reduction in heart malondialdehyde (MDA) and heart 3-nitrotyrosine (a reliable
indicator of tissue injury) levels occurred parallel to a significant increase in mean arterial pressure and to a
significant reduction in heart rate and cardiac output compared with untreated controls that showed a typical
hypotensive, hyperdynamic response to the injury (P < 0.05). In addition, rhAPC significantly attenuated the
changes in microvascular blood flow to the trachea, kidney, and spleen compared with untreated controls (P <
0.05 each). Blood flow to the ileum and pancreas, however, remained similar between groups. The cerebral blood
flow as measured in cerebral cortex, cerebellum, thalamus, pons, and hypothalamus, was significantly increased in
untreated controls, due to a loss of cerebral autoregulation in septic shock. rhAPC stabilized cerebral blood flow at
baseline levels, as in the sham group.
Conclusions: We conclude that rhAPC stabilized cardiovascular functions and attenuated the changes in visceral
and cerebral microcirculation in sheep suffering from ALI and septic shock by reduction of cardiac MDA and 3-
nitrotyrosine.
Introduction
Every year, more than 750,000 patients in the United
States develop sepsis, and 20 to 40% of these patients die
[1]. The current understanding of the pathophysiology of
sepsis is that inflammation, coagulation, and apoptosis
are linked in the disease process [2]. Recombinant
human activated protein C (rhAPC), a natural anticoagu-
lant, is the first biological agent to have shown a signifi-
cant survival benefit in patients with sepsis [3]. The
protective effect of rhAPC in patients with severe sepsis
is likely to reflect the ability of activated protein C (APC)
to modulate multiple pathways. In addition to its
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tory and apoptotic responses [2].
Doubts about the beneficial protective effects of APC
have persisted, however, and have been refueled by the
recently published negative trials in less severely ill
patients [4] and in children [5]. Infusion of rhAPC in
human models of endotoxemia was also not shown to
have any significant effect on proinflammatory responses
or on thrombin generation [6,7].
Our group has recently shown that rhAPC improved
pulmonary function in an ovine model of septic shock
and pneumonia [8]. The improved oxygenation was
based on a significant reduction of lung tissue 3-nitro-
tyrosine (3-NT), a reliable indicator of tissue injury
caused by reactive nitrogen species such as peroxynitrite
(ONOO
-) [8]. Since it is known that ONOO
- formation
is linked to the regulation of vascular tone [9], and that
rhAPC has been shown to improve capillary perfusion
from lipopolysaccharide-mediated microcirculatory dys-
function [10] and may attenuate intestinal ischemia/
reperfusion-induced injury [11], we hypothesized that
rhAPC administration likewise improves global hemody-
namics and regional microvascular blood flow during
septic shock.
On the basis of these observations and continuing
controversy, it seems important to re-explore the effects
of APC in relevant animal models. We therefore used a
clinically relevant sepsis model to investigate whether
APC could have beneficial therapeutic effects in septic
shock.
Materials and methods
The Institutional Animal Care and Use Committee of
the University of Texas Medical Branch at Galveston
approved the present study. The Investigational Inten-
sive Care Unit at University of Texas Medical Branch is
an Association for Assessment and Accreditation of
Laboratory Animal Care International-approved facility.
The guidelines of the National Institutes of Health for
the care and use of experimental animals were carefully
followed. The animals were individually housed in meta-
bolic cages and were studied in the awake state.
Experimental protocol
Twenty-one female Merino sheep (37 ± 2 kg) were
included in the present study. For the operative proce-
dures, sheep were anesthetized, and under aseptic condi-
tions the animals were chronically instrumented for
hemodynamic monitoring with a right femoral artery
catheter, a 7-French Swan-Ganz™ thermodilution cathe-
ter, and a left atrial catheter, as previously described
[12]. Following the surgical procedure, catheters were
flushed with heparin, and the animals were allowed to
recover for 7 days. During this time they had free access
to food and water.
One day before the experiment commenced, catheters
were connected to pressure transducers (Model PX3X3;
Baxter Edwards Critical Care Division, Irvine, CA, USA)
with continuous flushing devices. Electronically calcu-
lated mean pressures were recorded on a monitor with
graphic and digital displays, and cardiac output (CO),
core body temperature, arterial blood gases, and carbox-
yhemoglobin (COHb) saturation were measured as
reported [13]. The cardiac index and the systemic vascu-
lar resistance index were calculated using standard
equations [14]. Protein concentrations in plasma were
measured with a refractometer.
Following a baseline (BL) measurement, sheep were
randomly allocated to one of three groups (n =7e a c h ) :
an uninjured, untreated sham group; an injured,
untreated control group; and an injured group treated
with rhAPC. A tracheostomy was performed under keta-
mine anesthesia (10 mg/kg), and a Foley urinary reten-
tion catheter was placed in all animals to measure urine
output. Anesthesia was then maintained using 1.5 to
2.5% halothane (Vedco Inc., St Joseph, MO, USA) in
oxygen. The animals allocated to the control and treat-
ment groups were subjected to smoke inhalation injury
(four sets of 12 breaths of cotton smoke, <40°C), accord-
ing to an established protocol [12]. The sham group
received four sets of 12 breaths of room air. Arterial
COHb plasma concentrations were determined after
each set of smoke or air inhalation and served as an
index of lung injury. After smoke inhalation, an experi-
mental bacterial solution (live Pseudomonas aeruginosa,
5×1 0
11 colony-forming units) was instilled into the
lungs of control and treatment animals using a broncho-
scope (Model PF-P40; Olympus America Inc. Melville,
NY, USA). The sham group received only the vehicle
(NaCl 0.9%). Anesthesia was then discontinued and the
sheep were allowed to awaken [12]. In the treatment
group, rhAPC was intravenously administered, using the
clinically established dose of 24 μg/kg/hour [3,8], which
also has been shown to be adequate in sheep [15,16].
The control group received only the vehicle (NaCl
0.9%). Both infusions were initiated 1 hour post injury,
and lasted until the end of the experiment.
All animals were mechanically ventilated (Servo-Venti-
lator 900C; Siemens, Elema, Sweden) with a FiO2 of 1.0,
an initial tidal volume of 15 ml/kg and a respiration rate
of 30/minute. For the duration of the 24-hour study per-
iod, ventilator settings were periodically adjusted to
maintain an arterial pressure of carbon dioxide (pCO2)
below BL values because this approach allows invasive
ventilation in sheep in the awake state. The ventilatory
settings were adapted to the physiology of the sheep.
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weight was used to prevent atelectasis. Such volumes
result in peak and plateau pressures of approximately
20 mmHg and are similar to a 6 to 8 to 10 ml/kg tidal
volume in humans, depending on individual lung compli-
ance. Positive end-expiratory pressure remained at a
fixed level of 6 cmH2O to avoid ventilation-related differ-
ences in the study groups. These ventilator settings were
chosen in accordance with those originally described for
this model by Murakami and colleagues [12].
All animals were fluid resuscitated, initially started
with an infusion rate of 2 ml/kg/hour lactated Ringer’s
solution. The infusion rate was then adjusted to main-
tain hematocrit at BL levels. During the 24-hour study
period, all animals had free access to food, but not to
water, to precisely control the fluid balance.
Measurement of plasma nitrate/nitrite formation
The concentration of total amount of nitric oxide meta-
bolites (NOx) in the plasma was measured intermittently
by a blinded co-investigator. Plasma samples were sub-
jected to NOx reduction using vanadium(III) as a redu-
cing agent in a commercial instrument (model 745;
Antek Instruments, Houston, TX, USA). The resulting
nitric oxide (NO) was measured with a chemilumines-
cent NO analyzer (model 7020; Antek) and was
recorded by dedicated software as the NO content
(in μM) [12].
Regional microvascular blood flow measurements
The determination of regional blood flow was
performed using colored microspheres. Approximately
5 million microspheres (15.0 ± 0.1 μm) were injected
into the left atrium at BL, 6, 12, and 24 hours, while
reference blood was withdrawn from the femoral arterial
catheter at a constant rate of 10 ml/minute. The color
of the microspheres was randomized for each injection.
During necropsy, representative transmural tissue sam-
ples were obtained from the distal trachea, pancreas,
spleen, both kidneys (cortex), and ileum. In addition,
brain tissue samples of the cerebral cortex, cerebellum,
thalamus, pons, and hypothalamus were obtained. All
these tissue samples were analyzed by Interactive Medi-
cal Technologies Ltd (Los Angeles, CA, USA) by deter-
mining the weight of each tissue sample, digesting the
entire sample in a high concentration of NaOH, and
measuring the total number of different colored spheres
using flow cytometry. Regional blood flow was then cal-
culated using the following formula [14,17]:
Regionalbloodflow ml minute g totaltissuespheres tissu (/ / )( ) / ( = e eweightg
referencespheres ml minute
, )
(/ / ) )
×
Necropsy
After completion of the experiment, the animals were
anesthetized with ketamine (15 mg/kg) and sacrificed by
intravenous injection of 60 ml saturated potassium
chloride. Immediately after death, heart tissue was
excised for determination of heart 3-NT, and heart mal-
ondialdehyde (MDA) as described below [18].
Quantification of malondialdehyde activity
MDA is a major end-product of oxidation of polyunsa-
turated fatty acids, and is frequently measured as an
indicator of lipid peroxidation and oxidative stress.
Using a commercially available kit, heart tissue was
homogenized (100 mg/ml) in 1.15% KCl buffer. To the
tissue homogenate, 20% trichloroacetic acid, 0.67%
thiobarbituric acid, and 2% butylated hydroxytoluene
were added, and the mixture was incubated for 30 min-
utes at 95°C. After cooling to room temperature,
n-butanol was also added and shaken vigorously. After
centrifugation at 2,500 × g for 10 minutes, the organic
layer was taken and its absorbance at 532 nm was
measured. 1,1,3,3-Tetramethoxypropane was used as
an external standard [18].
ELISA for heart 3-nitrotyrosine
Quantification of heart tissue 3-NT content was ana-
lyzed using ELISA as previously described [18]. Briefly,
2 ml of 10× diluted homogenation buffer (1:10; Cayman
Chemical, Ann Arbor, MI, USA) containing 250 mM
Tris-HCl (pH 7.4), 10 mM ethylenediamine tetraacetic
acid and 10 mM ethyleneglycol-bis(b-aminoethylether)-
N,N,N’,N’-tetraacetic acid were added to 200 mg freshly
frozen heart tissue and then homogenized. Following
centrifugation (10,000 × g at 4°C) for 15 minutes,
100 μg supernatant was used for assessment of 3-NT.
Measurements were performed using the HyCult bio-
technology 3-NT solid-phase ELISA (Cell Sciences Inc,
Canton, MA, USA), and were strictly performed accord-
ing to the manufacturer’s protocol.
Following incubation for 1 hour, the plate was emp-
tied and washed three times (20 seconds each) using
200 μl wash buffer provided with the kit. Thereafter,
100 μl diluted tracer were added to each well and incu-
bated for 1 hour. Following the washing process, 100 μl
diluted streptavidin-peroxidase conjugate was added and
incubated for an additional hour. After having repeated
the washing procedure, 100 μl freshly prepared tetra-
methylbenzidine were added and incubated for 25 min-
utes. The reaction was then stopped by adding 100 μl
stop solution to the samples. Finally, the tray was placed
in a spectrophotometer and the absorbance determined
at a wavelength of 450 nm, following the instructions
provided by the manufacturer.
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For statistical analysis, Sigma Stat 2.03 software (SPSS
Inc., Chicago, IL, USA) was used. After confirming a
normal distribution (Kolmogorov-Smirnov test), a two-
way analysis of variance for repeated measurements with
appropriate Student-Newman-Keuls post hoc compari-
sons was used to detect differences within and between
groups. Significance was assumed when P < 0.05. Data
are presented as means ± standard errors of the mean.
Results
Injury and survival
The arterial COHb determined immediately after the
fourth set of smoke exposure averaged 73 ± 5% in
the control group and 70 ± 4% in the rhAPC group.
The sham group, which was not exposed to smoke inha-
lation, showed a COHb level of 5 ± 1% after giving four
sets of 12 breaths of room air. No significant difference
was determined in COHb levels (P > 0.05) for the
injured groups, reflecting the consistency of the injury.
With aggressive fluid challenge, all animals survived the
24-hour study period.
Global hemodynamics
Cardiovascular variables were stable in sham animals. In
the control group, the heart rate and CO increased sig-
nificantly after 24 hours and were associated with a sig-
nificant drop in mean arterial pressure (MAP) (Figure 1
each P < 0.05 vs. BL). In rhAPC-treated sheep, the CO
and heart rate remained stable, and MAP did not fall to
the same extent as in control sheep (each P < 0.05).
Global hemodynamic data are presented in Table 1.
Regional microvascular blood flow
The regional microvascular blood flow in all sham ani-
mals remained near BL levels and showed no statistical
difference to BL. In the trachea, below the tracheostomy
tube, blood flow dramatically increased in control ani-
mals during the entire experiment versus BL, versus
sham, and versus rhAPC-treated sheep (Figure 2 P <
0.05). In addition, the regional microvascular blood flow
of control animals in both kidneys as well as in the pan-
creas significantly decreased over time versus BL and
versus sham animals (P < 0.05 each). Pancreatic blood
flow in the control group was lower, but was not statis-
tically different from the rhAPC group (Table 2). Blood
flow in both kidneys, however, did not fall to the same
extent in rhAPC-treated sheep and was significantly
attenuated over time (P < 0.05, Figure 1). In the spleen,
blood flow significantly increased in controls compared
with BL, sham, and rhAPC groups (P < 0.05, Figure 2).
The regional microvascular blood flow in the ileum sig-
nificantly increased in controls, compared with BL and
sham animals (P < 0.05, Table 2), but was not statisti-
cally different compared with the rhAPC group.
The cerebral blood flow was measured in the cerebral
cortex, cerebellum, thalamus, pons, and hypothalamus.
In all these areas of control animals, cerebral blood flow
was significantly increased compared with BL, sham,
and rhAPC animals (P < 0.05, Figure 2 and Table 2).
There was no statistical difference between sham and
rhAPC.
Plasma nitrate/nitrite levels
Plasma NOx levels increased significantly over time in
the control and rhAPC groups, as compared with the
sham group (P < 0.05). There was no statistical differ-
ence between the two injured groups (Table 1).
Plasma oncotic pressure
The plasma oncotic pressure was significantly decreased
in both injured groups versus BL and versus the sham
group, which remained at BL levels (P < 0.05). The
reduction in plasma oncotic pressure was significantly
attenuated in the rhAPC group as compared with the
control group (P < 0.05, Table 1).
Pulmonary function
The pulmonary variables showed similar results as pre-
viously described, and are presented in Table 1.
Tissue analysis
The results for heart 3-NT are shown in Figure 3. The
control group showed a significantly higher protein con-
centration than the sham group (P < 0.05). The concen-
tration in the rhAPC group showed no statistical
difference to the sham group, but was significantly
lower (P < 0.05) than in the control group.
Heart MDA levels (μM/ml/mg) of controls were sig-
nificantly higher than sham or rhAPC levels (P < 0.05,
Figure 3). There was no statistical difference between
sham and rhAPC animals.
Total fluid balance
Over 24 hours, the total urine output in sham animals
(3,459 ± plusorminus 289 ml) was significantly higher
than in control animals (1,353 ± plusorminus 260 ml)
and rhAPC animals (2,049 ± plusorminus 170 ml, P <
0.05 each). Urine output in rhAPC-treated animals was
significantly higher than in controls (P < 0.05).
The sham group received a total of 1,832 ± plusormi-
nus 119 ml fluids. This fluid intake was significantly less
than in controls (3,534 ± plusorminus 529 ml) or
rhAPC animals (5,019 ± plusorminus 1,091 ml; P <0 . 0 5
each). The fluid intake in the rhAPC group was signifi-
cantly greater than in controls (P < 0.05).
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subtracted from the total fluid intake over 24 hours,
when started with a rate of 2 ml/kg/hour. The control
group (2,181 ± 577 ml) and the rhAPC group (2,970 ±
1,076 ml) both had significantly greater positive fluid
balances than the sham group (-1,627 ± 227 ml, P <
0.05 each). There was no difference between the injured
groups.
Temperature
Core body temperature remained at baseline in the sham
group. The control and rhAPC group showed a signifi-
cant increase in temperature as compared with the sham
group and versus BL (P < 0.05). There was no statistical
difference between the injured groups (Table 1).
Discussion
The present study investigated the effects of rhAPC on
global hemodynamics and regional microvascular blood
flow in an established and clinically relevant model of
septic shock resulting from smoke inhalation injury
[8,12-14]. The major finding was a significantly improved
cardiovascular function by rhAPC treatment, indexed by
stabilized MAP, heart rate, and CO as well as attenuated
changes in visceral and cerebral microcirculation to cer-
tain organs. Whereas blood flow of the ileum and pan-
creas remained unchanged between the injured groups,
the changes in blood flow to the renal cortex, spleen, tra-
chea, cerebral cortex, cerebellum, thalamus, pons, and
hypothalamus were attenuated in the rhAPC-treated
group.
The sheep model of acute lung injury (ALI) and septic
shock is suitable for studying the effects of sepsis,
because it closely mimics the pathophysiology of human
sepsis [12]. This two-hit model fulfills the criteria of
sepsis as described by Bone and colleagues [19], and
would lead to decreased regional microvascular blood
flow to most, if not all, vital organs - thereby mimicking
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Page 5 of 12Table 1 Global hemodynamics
Parameter Group BL = 0 hours 3 hours 6 hours 12 hours 18 hours 24 hours
CVP (mmHg) Sham 7 ± 1 13 ± 2
# 12 ± 1
# 11 ± 1
# 10 ± 1
# 10 ± 1
#
Control 6 ± 1 9 ± 1
# 11 ± 1
# 13 ± 1
# 14 ± 1
#† 15 ± 1
#†
rhAPC 5 ± 1 10 ± 1
# 11 ± 1
# 11 ± 1
# 13 ± 1
# 13 ± 2
#
MPAP (mmHg) Sham 23 ± 1 26 ± 1 27 ± 1 26 ± 1 26 ± 1 27 ± 1
#
Control 21 ± 1 26 ± 2
# 31 ± 2
#† 28 ± 1
# 30 ± 1
# 33 ± 1
#†
rhAPC 20 ± 1 25 ± 1
# 25 ± 1
#*2 7 ± 2
# 30 ± 2
# 28 ± 2
#*
PAOP (mmHg) Sham 11 ± 1 14 ± 1
# 15 ± 1
# 14 ± 1
# 16 ± 1
# 14 ± 1
#
Control 10 ± 1 15 ± 1
# 16 ± 1
# 17 ± 1
# 17 ± 1
# 18 ± 1
#†
rhAPC 11 ± 1 16 ± 1
# 16 ± 1
# 17 ± 1
# 17 ± 1
# 16 ± 1
#*
LAP (mmHg) Sham 7 ± 0 9 ± 1
# 10 ± 1
# 9±1
# 9±1
# 9±1
#
Control 7 ± 1 11 ± 1
# 15 ± 2
#† 15 ± 1
#† 17 ± 1
† 19 ± 1
#†
rhAPC 9 ± 2 9 ± 1 11 ± 1* 13 ± 1
#† 15 ± 1
#† 14 ± 2
#†*
CI (l/min/m
2) Sham 5.6 ± 0.1 5.3 ± 0.3 5.1 ± 0.1 4.8 ± 0.1 4.8 ± 0.1 4.6 ± 0.1
Control 5.3 ± 0.3 5.8 ± 0.5 6.2 ± 0.4
#† 6.5 ± 0.3
#† 6.9 ± 0.3
#† 8.7 ± 0.4
#†
rhAPC 5.0 ± 0.2 5.2 ± 0.4 5.5 ± 0.4 5.7 ± 0.3
†* 6.1 ± 0.2
#†* 6.2 ± 0.2
#†*
SVRI (dyne s/cm
5/m
2) Sham 1289 ± 87 1374 ± 133 1402 ± 103 1502 ± 64 1576 ± 79 1599 ± 96
Control 1419 ± 59 1224 ± 92 1128 ± 85
# 740 ± 50
#† 632 ± 52
#† 502 ± 42
#†
rhAPC 1464 ± 79 1364 ± 187 1334 ± 188 1111 ± 64
#†* 968 ± 51
#†* 934 ± 41
#†*
PaO2:FiO2 ratio Sham 506 ± 10 471 ± 11 490 ± 18 492 ± 17 498 ± 16 491 ± 19
Control 521 ± 19 202 ± 36
#† 144 ± 26
#† 72 ± 5
#† 72 ± 7
#† 74 ± 6
#†
rhAPC 541 ± 10 245 ± 56
#† 176 ± 39
#† 151 ± 24
#†* 134 ± 22
#†* 118 ± 17
#†
PaCO2 (mmHg) Sham 32 ± 1 29 ± 1 26 ± 1
# 25 ± 1
# 23 ± 2
# 24 ± 1
#
Control 37 ± 2 29 ± 3
# 27 ± 3
# 28 ± 2
# 29 ± 0
# 29 ± 2
#
rhAPC 36 ± 0 25 ± 3
# 27 ± 2
# 25 ± 2
# 27 ± 2
# 27 ± 4
#
apH (-log10[H
+]) Sham 7.469 ± 0.012 7.542 ± 0.027
# 7.537 ± 0.014
# 7.558 ± 0.019
# 7.583 ± 0.015
# 7.548 ± 0.026
#
Control 7.449 ± 0.014 7.577 ± 0.031
# 7.564 ± 0.025
# 7.525 ± 0.012
# 7.465 ± 0.031
† 7.437 ± 0.027
†
rhAPC 7.470 ± 0.010 7.622 ± 0.026
#† 7.590 ± 0.018
# 7.556 ± 0.016
# 7.509 ± 0.024
† 7.480 ± 0.043
†
DO2I (ml/min/m
2) Sham 607 ± 33 651 ± 49 648 ± 57 567 ± 48 565 ± 38 551 ± 41
Control 580 ± 70 663 ± 58 719 ± 62# 709 ± 27
# 726 ± 67
# 984 ± 82
#†
rhAPC 624 ± 32 638 ± 43 690 ± 51 644 ± 56 650 ± 40 666 ± 37
#*
VO2I (ml/min/m
2) Sham 209 ± 21 198 ± 26 183 ± 21 170 ± 21 195 ± 31 165 ± 23
Control 242 ± 24 220 ± 30 231 ± 30 215 ± 35 178 ± 29 274 ± 41
rhAPC 197 ± 16 244 ± 24 227 ± 24 193 ± 31 186 ± 25 253 ± 39
Temperature (°C) Sham 39.0 ± 0.1 39.5 ± 0.1 39.5 ± 0.1 39.2 ± 0.2 39.1 ± 0.1 39.2 ± 0.1
Control 39.1 ± 0.1 40.2 ± 0.2
#† 40.5 ± 0.2
#† 40.4 ± 0.2
#† 40.1 ± 0.2
#† 40.1 ± 0.3
#†
rhAPC 39.3 ± 0.1 40.0 ± 0.2
#† 40.5 ± 0.2
#† 40.5 ± 0.1
#† 40.4 ± 0.2
#† 40.4 ± 0.1
#†
Hematocrit (%) Sham 25.2 ± 0.8 26.2 ± 1.2 26.0 ± 1.6 25.0 ± 1.3 24.7 ± 1.0 24.7 ± 1.0
Control 25.3 ± 1.0 27.5 ± 0.9
# 28.3 ± 0.8
# 29.7 ± 0.9
#† 28.8 ± 1.2
# 28.9 ± 0.7
#†
rhAPC 28.2 ± 0.9 27.7 ± 1.1 29.7 ± 1.3 28.3 ± 0.9
† 28.3 ± 1.0 27.2 ± 0.7
†
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tiorgan dysfunction syndrome [14].
Our group has recently shown that rhAPC improved
pulmonary function in this ovine model by reduction of
airway obstruction and lung tissue 3-NT levels, a reli-
able indicator of tissue injury caused by reactive
nitrogen species such as ONOO
- [8]. In the latter study,
the activated clotting time and platelet count remained
stable in rhAPC-treated animals. In addition, rhAPC
prevented disseminated intravascular coagulation.
Among the various anticoagulants, rhAPC is an espe-
cially important compound as it has shown a significant
Table 1 Global hemodynamics (Continued)
Plasma NOx (μM) Sham 5.0 ± 0.6 5.4 ± 0.6 5.4 ± 0.8 5.0 ± 0.9 5.8 ± 0.7 6.0 ± 0.7
Control 5.2 ± 0.5 7.1 ± 0.8
# 7.9 ± 0.8
#† 9.0 ± 1.2
#† 9.8 ± 1.1
#† 10.5 ± 1.1
#†
rhAPC 4.6 ± 0.6 7.8 ± 0.6
# 9.4 ± 0.5
#† 9.6 ± 1.1
#† 9.5 ± 1.1
#† 8.9 ± 0.8
#†
Plasma Onc (mmHg) Sham 21.9 ± 0.4 20.9 ± 0.7 20.2 ± 0.9 20.8 ± 0.6 22.1 ± 0.5 22.5 ± 0.7
Control 22.7 ± 0.9 19.5 ± 0.4
# 16.2 ± 0.7
#† 14.4 ± 0.7
#† 12.5 ± 0.8
#† 10.9 ± 1.0
#†
rhAPC 24.3 ± 0.4 22.7 ± 0.3* 21.0 ± 0.3
#* 18.3 ± 0.7
#†* 15.9 ± 1.3
#†* 14.7 ± 1.5
#†*
CVP, central venous pressure; MPAP, mean pulmonary artery pressure; PAOP, pulmonary artery occlusion pressure; LAP, left atrial pressure; CI, cardiac index; SVRI,
systemic vascular resistance index; PaO2:FiO2 ratio, Horovitz quotient; PaCO2, arterial carbon dioxide partial pressure; apH, arterial pH; DO2I, oxygen delivery index;
VO2I, oxygen consumption index; NOx, nitrate-to-nitrite formation; Onc, oncotic pressure; rhAPC, recombinant human activated protein C. P ≤0.05:
#versus
baseline,
†versus sham, *versus control.
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Parameter Group BL = 0 hours 6 hours 12 hours 24 hours
Cardiac index (l/min/m
2) Sham 100 ± 0 90.7 ± 2.8 86.2 ± 3.0 82.5 ± 3.0
Control 100 ± 0 117.1 ± 10.0 122.7 ± 5.9
#† 166.2 ± 16.2
#†
rhAPC 100 ± 0 109.6 ± 9.2 113.2 ± 6.6*
† 124.2 ± 6.9*
†
Pancreas (%) Sham 100 ± 0 97.3 ± 10.5 94.9 ± 8.1 104.0 ± 16.1
Control 100 ± 0 55.5 ± 9.3 60.5 ± 12.3
# 52.3 ± 6.9
#†
rhAPC 100 ± 0 76.5 ± 9.5 61.3 ± 9.5
# 65.5 ± 15.2
#
Ileum (%) Sham 100 ± 0 95.4 ± 20.2 89.1 ± 11.3 111.8 ± 23.5
Control 100 ± 0 102.4 ± 13.5 156.0 ± 38.6
#† 135.1 ± 28.1
rhAPC 100 ± 0 95.6 ± 9.2 107.8 ± 19.0 136.0 ± 32.3
Medulla oblongata (%) Sham 100 ± 0 91.3 ± 11.2 95.5 ± 8.3 93.1 ± 17.1
Control 100 ± 0 78.1 ± 7.1 132.1 ± 17.5 145.0 ± 16.7
#
rhAPC 100 ± 0 75.3 ± 9.3 89.6 ± 22.4 97.2 ± 16.9
Thalamus (%) Sham 100 ± 0 92.6 ± 7.4 95.2 ± 9.9 93.9 ± 13.8
Control 100 ± 0 90.2 ± 9.3 137.0 ± 18.1
# 157.7 ± 31.6
#
rhAPC 100 ± 0 96.1 ± 4.8 95.8 ± 9.1* 107.5 ± 10.3*
Pons (%) Sham 100 ± 0 95.9 ± 9.9 92.6 ± 7.5 96.1 ± 18.3
Control 100 ± 0 87.7 ± 8.8 130.0 ± 14.7
# 167.3 ± 26.7
#†
rhAPC 100 ± 0 78.1 ± 6.0 81.8 ± 9.1* 104.4 ± 15.5*
Regional microvascular blood flow (percentage from baseline). rhAPC, recombinant human activated protein C. P ≤0.05:
#vs. BL, *vs. control,
†vs. sham.
p ≤ 0.05; * vs. Control, †vs. Sham 
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Page 8 of 12survival benefit in patients with severe sepsis [3]. The
positive effects of rhAPC on pulmonary function in dif-
ferent models of ALI are well described [8,15,16,20-22].
The nonpulmonary, systemic effects of ALI, however,
remain to be investigated.
Kalil and colleagues have shown that rhAPC contribu-
ted to an increase in MAP after endotoxin exposure of
volunteers [6], and Monnet and colleagues reported that
APC administration required less norepinephrine to
maintain arterial blood pressure [23]. Wang and collea-
gues demonstrated beneficial cardiopulmonary effects of
rhAPC in an ewe model of sepsis caused by peritonitis
[24]. The pulmonary effects were comparable with our
previous findings [8]. The exact mechanisms of the
improved hemodynamic effects of rhAPC, however, are
still not well defined. Hauser and colleagues recently
described that overproduction of NO by inducible nitric
oxide synthase is critically involved in the pathogenesis of
circulatory shock [25]. Not only NO itself, via cyclic gua-
nosine monophosphate-mediated smooth muscle relaxa-
tion, but also its downstream biological effects may play a
role in arterial hypotension [26]. ONOO
- is a highly toxic
reactive species formed from NO and superoxide (O2
-),
and is capable of inducing endothelial dysfunction and
vascular hyporeactivity [27]. Recent data showed the
implication of ONOO
- in the inactivation of a1-adrenore-
ceptors [28] and norepinephrine [29], and showed that
superoxide deactivates catecholamines, resulting in loss of
their vasopressor activity, consecutively resulting in hypo-
tension [30]. Since we have previously shown significantly
reduced pulmonary 3-NT levels of rhAPC-treated
animals compared with controls in this model [8], we
hypothesized that there is a link between rhAPC,
ONOO
- and vascular regulatory mechanisms. The data of
our present study clearly show less cardiac 3-NT forma-
tion, indicating less production of reactive nitrogen spe-
cies such as ONOO
- following rhAPC infusion in ALI
and septic shock. This, in turn, was associated with
improved vascular tone and improved MAP as well as
the systemic vascular resistance index. The attenuation of
changes in organ perfusion necessitated less compensa-
tory increase of the heart rate and CO.
In this context, it is well known that the interaction
between leukocytes and endothelial cells is critical in
endothelial cell damage. In our study there was no dif-
ference in NOx levels between the injured groups. This
finding stands in contrast to the findings of Isobe and
colleagues, who reported that APC prevented endo-
toxin-induced hypotension in rats by the inhibition of
NO [31]. This contradiction might be related to the dif-
ferent species used, as well as to the timing of treatment
in different animal models [20]. In our study, it is most
probable that the prevention of 3-NT formation resulted
from a reduction in oxidative stress as indicated by
significantly reduced cardiac MDA levels. Sturn and col-
leagues demonstrated that neutrophils express receptors
for APC, and also that neutrophil chemotaxis is inhib-
ited by exposure to protein C, APC, or rhAPC [32].
APC can improve the visceral microcirculation by
attenuating leukocyte-endothelial interactions and leuko-
cyte rolling [33].
Importantly, Marechal and colleagues have shown that
the endothelial glycocalyx is extremely sensitive to free
radicals [34]. Oxidative stress was evaluated by oxidation
of dihydrorhodamine in microvascular beds and levels of
heart MDA and plasma carbonyl proteins, which were
all increased in lipopolysaccharide-treated rats. APC
enhanced the systemic arterial pressure response to
norepinephrine in lipopolysaccharide-treated rats, and
prevented capillary perfusion deficit in the septic micro-
vasculature that was associated with reduced oxidative
stress and preservation of the glycocalyx. It is obvious
that lipopolysaccharide-induced major microcirculation
dysfunction accompanied by microvascular oxidative
stress and glycocalyx degradation may be limited by
APC. This is in line with our findings, clearly showing
that reduction in cardiac MDA and 3-NT led to attenu-
ated changes in microvascular blood flow to eight out of
10 investigated organs. In our study, the attenuated
drop in renal blood flow in rhAPC-treated animals,
resulting from decreased MDA and 3-NT levels, is also
in accordance with the findings of Gupta and colleagues,
who demonstrated that administration of APC improved
systemic hemodynamics and protected from renal dys-
function [35]. The antithrombotic properties [8] and
cytoprotective properties [35] of APC further contribute
to improved organ blood flow. The dramatic increase of
tracheal blood flow in the present study was anticipated,
given the degree of direct inflammatory damage by
smoke inhalation at this site [14,17]; however, the signif-
icant decrease in tracheal blood flow of rhAPC-treated
animals may be a direct anti-inflammatory effect. Blood
flow to the ileum increased continuously in control ani-
mals, but rhAPC-treated sheep showed a significantly
lower ileal blood flow at 12 hours post injury than con-
trols. This might be considered a disadvantage of the
rhAPC treatment, since restricted gut perfusion is
known to result in bacterial translocation. The impor-
tance of this finding may remain controversial, however,
because the blood flow in rhAPC-treated sheep was
statistically not different from that of healthy sham
animals.
In respect of cerebral blood flow, it is noteworthy that
all animals in our study were moderately hyperventilated
and were not sedated - to allow mechanical ventilation
in the awake state, and to exclude the impact that seda-
tive or narcotic drugs have on vascular tone. The
unchanged blood flow in the sham group supports the
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Page 9 of 12ventilation-related decrease in PaCO2 and the corre-
sponding increase in arterial pH having no influence on
cerebral blood flow in this model, and the PaCO2 as
well as arterial pH were similar between all groups. The
increase in cerebral blood flow in control animals is
most probably due to a loss of cerebral autoregulation
during hypotensive, hyperdynamic shock states, and
consecutive hypoxia, displayed by the significant drop in
the PaO2/FiO2 ratio in the control group. The decrease
in cardiac MDA and 3-NT levels in rhAPC-treated ani-
mals led to improved systemic hemodynamics within
the limits of the cerebral autoregulation, thereby stabi-
lizing cerebral blood flow. APC has also been shown to
cross the blood-brain barrier [36] and to have neuropro-
tective effects in ischemic stroke models [37] and heat
stroke models [38]. The origin of cerebral dysfunction
in patients with sepsis is still unclear and may be related
to increased intracranial pressure due to increased cere-
bral blood flow. Little is known, however, about the
effects of rhAPC in this setting.
A limitation of the present study might be that regional
microvascular blood flow, although correctly used as a
term, is not identical to microvascular perfusion, as per-
fusion of vessels below 15 μm could not be evaluated.
In the present study, the total urine output in rhAPC-
treated animals was significantly higher than in controls,
suggesting increased renal perfusion. The fluid resuscita-
tion in all investigated animals was adjusted hourly to
maintain hematocrit and to prevent hemoconcentration
or hemodilution. The fluid intake in controls was signifi-
cantly less than in rhAPC animals because, based on an
increased urine output, greater amounts of fluids had to
be administered in rhAPC-treated sheep to maintain
hematocrit. Even though there was no statistical differ-
ence in the fluid balance between the injured groups,
however, some of the macrohemodynamic and microhe-
modynamic findings with rhAPC may be related to a
slightly higher fluid balance in the treatment group.
Further research on the effects of rhAPC on renal perfu-
sion is necessary to draw final conclusions.
The perfect approach of how to ventilate and what
FiO2 value to use remains a controversial discussion. One
could argue that a FiO2 o f1 . 0a su s e di no u rs t u d yc o u l d
lead to hyperoxia-induced pulmonary injury. Murakami
and colleagues, however, have shown that a FiO2 of 1.0
in this model is safe up to 48 hours [12]. In addition,
Hauser and colleagues [39] and Barth and colleagues [40]
could show that hyperoxia may have protective effects
during the early and late phases of septic shock in a
swine model, which may lead to future investigations.
Conclusions
The present study is the first demonstrating a link
between rhAPC and the reduction of cardiac MDA and
3-NT levels with improved global hemodynamics as well
as attenuated changes in visceral and cerebral microvas-
cular blood flow in ALI and septic shock. Future studies
are necessary to further investigate the role of rhAPC
on cardiovascular function and cerebral blood flow.
Key messages
￿ rhAPC reduced cardiac MDA levels in septic
shock.
￿ rhAPC reduced cardiac 3-NT levels in septic
shock.
￿ rhAPC improved global hemodynamics in septic
shock.
￿ rhAPC attenuated changes in microcirculation in
septic shock.
Abbreviations
ALI: acute lung injury; APC: activated protein C; BL: baseline; CO: cardiac
output; COHb: carboxyhemoglobin; ELISA: enzyme-linked immunosorbent
assay; FiO2: fraction of inspired oxygen; MAP: mean arterial pressure; MDA:
malondialdehyde; NO: nitric oxide; NOx: total amount of nitric oxide
metabolites; 3-NT: 3-nitrotyrosine; ONOO
-, peroxynitrite; PaCO2: partial
pressure of arterial carbon dioxide in the blood; rhAPC: recombinant human
activated protein C.
Acknowledgements
The present work was supported in part by grants for the following authors:
grant GM066312 from the National Institutes of Health (DLT), grants 8820
and 8450 from the Shriners of North America (DLT and DNH), an industrial
grant from Eli Lilly & Co Australia (JFF), and National Institutes of Health
grant R01 GM060915 (CS). All other authors received no funding. None of
the funding sources played any role in study design; in the collection,
analysis, and interpretation of data; in the writing of the manuscript; or in
the decision to submit the manuscript for publication.
Author details
1Department of Anesthesiology, Investigational Intensive Care Unit, The
University of Texas Medical Branch and Shriners Burns Hospital for Children,
301 University Blvd, Galveston, TX 77555-0591, USA.
2Department of
Anaesthesiology and Intensive Care, Philipps University of Marburg, Baldinger
Str. 1, Marburg 35033, Germany.
3Critical Care Research Group, University of
Queensland and The Prince Charles Hospital at Brisbane, Rode Road,
Chermside 4032, Queensland, Australia.
4Institute of Human Physiology and
Clinical Experimental Research, Semmelweis University, Tćzoltó utca 37-47,
Budapest 1094, Hungary.
5Department of Surgery, The University of Texas
Medical Branch and Shriners Burns Hospital for Children, 815 Market Street,
Galveston, TX 77550-2725, USA.
Authors’ contributions
MOM and DMM designed and carried out the experiments, analyzed and
interpreted the data, and drafted the manuscript and revised it critically for
important intellectual content. JFF contributed grant support and study
design, carried out experiments, and revised the manuscript critically for
important intellectual content. DLT contributed grant support, study design
and interpretation of the data. CS contributed grant support and data
interpretation. MW, LK and EMH performed 3-NT and MDA measurements,
collected and analyzed samples, and interpreted some data. YN and LDT
performed the complicated surgeries, and collected and analyzed data. DNH
contributed with grant support, experimental design and data interpretation.
All authors read and approved the final manuscript, and decided on
submission to Critical Care.
Competing interests
The authors declare that they have no competing interests. In the present
study, some animals from a previous study [8] were used. The previous
Maybauer et al. Critical Care 2010, 14:R217
http://ccforum.com/content/14/6/R217
Page 10 of 12study, however, reported data for pulmonary injury and airway obstruction.
The hemodynamic and microcirculatory data of the present study are
original and have not been previously published.
Received: 6 May 2010 Revised: 15 July 2010
Accepted: 26 November 2010 Published: 26 November 2010
References
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR:
Epidemiology of severe sepsis in the United States: analysis of
incidence, outcome, and associated costs of care. Crit Care Med 2001,
29:1303-1310.
2. Liaw PC: Endogenous protein C activation in patients with severe sepsis.
Crit Care Med 2004, 32:S214-S218.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr:
Efficacy and safety of recombinant human activated protein C for severe
sepsis. N Engl J Med 2001, 344:699-709.
4. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B,
Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A,
Arkins N, Utterback BG, Macias WL: Drotrecogin alfa (activated) for adults
with severe sepsis and a low risk of death. N Engl J Med 2005,
353:1332-1341.
5. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-
Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B: Drotrecogin alfa
(activated) in children with severe sepsis: a multicentre phase III
randomised controlled trial. Lancet 2007, 369:836-843.
6. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP,
Nelson DR, Lowry SF: Effects of drotrecogin alfa (activated) in human
endotoxemia. Shock 2004, 21:222-229.
7. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B:
Recombinant human activated protein C (rhAPC; drotrecogin alfa
[activated]) has minimal effect on markers of coagulation, fibrinolysis,
and inflammation in acute human endotoxemia. Blood 2003,
102:2093-2098.
8. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M,
Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K,
Mizutani A, Herndon DN, Traber DL: Recombinant human activated
protein C improves pulmonary function in ovine acute lung injury
resulting from smoke inhalation and sepsis. Crit Care Med 2006,
34:2432-2438.
9. Asfar P, Hauser B, Radermacher P, Matejovic M: Catecholamines and
vasopressin during critical illness. Crit Care Clin 2006, 22:131-149, vii-viii.
10. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J,
Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms
of activated protein C action during endotoxemia. Crit Care Med 2004,
32:1011-1017.
11. Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, van Gulik TM:
Inhibition of coagulation and inflammation by activated protein C or
antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit
Care Med 2004, 32:1375-1383.
12. Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK,
Herndon DN, Traber LD, Traber DL: A novel animal model of sepsis after
acute lung injury in sheep. Crit Care Med 2002, 30:2083-2090.
13. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Cox RA,
Huda R, Nakano YY, Enkhbaatar P, Hawkins HK, Herndon DN, Traber DL:
Ceftazidime improves hemodynamics and oxygenation in ovine smoke
inhalation injury and septic shock. Intensive Care Med 2007, 33:1219-1227.
14. Maybauer DM, Maybauer MO, Traber LD, Westphal M, Nakano YY,
Enkhbaatar P, Morita N, Herndon DN, Traber DL: Effects of severe smoke
inhalation injury and septic shock on global hemodynamics and
microvascular blood flow in sheep. Shock 2006, 26:489-495.
15. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B,
Ingebretsen OC, Ytrehus K, Bjertnaes LJ: Recombinant human activated
protein C attenuates endotoxin-induced lung injury in awake sheep. Crit
Care 2008, 12:R104.
16. Waerhaug K, Kirov MY, Kuzkov VV, Kuklin VN, Bjertnaes LJ: Recombinant
human activated protein C ameliorates oleic acid-induced lung injury in
awake sheep. Crit Care 2008, 12:R146.
17. Schenarts PJ, Bone HG, Traber LD, Traber DL: Effect of severe smoke
inhalation injury on systemic microvascular blood flow in sheep. Shock
1996, 6:201-205.
18. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK,
Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL, Traber DL:
Effect of poly(ADP ribose) synthetase inhibition on burn and smoke
inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 2003, 285:
L240-L249.
19. Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference
on sepsis and organ failure. Chest 1992, 101:1481-1483.
20. Velik-Salchner C, Wenzel V, Maybauer DM, Maybauer MO: Recombinant
human activated protein C in experimental models of acute lung injury:
the timing is critical! Intensive Care Med 2007, 33:2048-2050.
21. Maybauer MO, Traber DL, Maybauer DM: Recombinant human activated
protein C in acute lung injury: what is the role of bronchial circulation?
Crit Care 2009, 13:112.
22. Waerhaug K, Kuzkov VV, Kuklin VN, Mortensen R, Nordhus KC, Kirov MY,
Bjertnaes LJ: Inhaled aerosolised recombinant human activated protein C
ameliorates endotoxin-induced lung injury in anaesthetised sheep. Crit
Care 2009, 13:R51.
23. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL: Rapid
and beneficial hemodynamic effects of activated protein C in septic
shock patients. Intensive Care Med 2005, 31:1573-1576.
24. Wang Z, Su F, Rogiers P, Vincent JL: Beneficial effects of recombinant
human activated protein C in a ewe model of septic shock. Crit Care Med
2007, 35:2594-2600.
25. Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B: Nitric oxide
synthase inhibition in sepsis? Lessons learned from large-animal studies.
Anesth Analg 2005, 101:488-498.
26. Maybauer DM, Maybauer MO, Szabo C, Westphal M, Traber LD,
Enkhbaatar P, Murthy KG, Nakano Y, Salzman AL, Herndon DN, Traber DL:
Lung-protective effects of the metalloporphyrinic peroxynitrite
decomposition catalyst WW-85 in interleukin-2 induced toxicity. Biochem
Biophys Res Commun 2008, 377:786-791.
27. Pacher P, Szabo C: Role of the peroxynitrite-poly(ADP-ribose) polymerase
pathway in human disease. Am J Pathol 2008, 173:2-13.
28. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S: Modification of
alpha1-adrenoceptors by peroxynitrite as a possible mechanism of
systemic hypotension in sepsis. Crit Care Med 2002, 30:894-899.
29. Takakura K, Xiaohong W, Takeuchi K, Yasuda Y, Fukuda S: Deactivation of
norepinephrine by peroxynitrite as a new pathogenesis in the
hypotension of septic shock. Anesthesiology 2003, 98:928-934.
30. Macarthur H, Couri DM, Wilken GH, Westfall TC, Lechner AJ, Matuschak GM,
Chen Z, Salvemini D: Modulation of serum cytokine levels by a novel
superoxide dismutase mimetic, M40401, in an Escherichia coli model of
septic shock: correlation with preserved circulating catecholamines. Crit
Care Med 2003, 31:237-245.
31. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K:
Activated protein C prevents endotoxin-induced hypotension in rats by
inhibiting excessive production of nitric oxide. Circulation 2001,
104:1171-1175.
32. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K,
Wiedermann CJ: Expression and function of the endothelial protein C
receptor in human neutrophils. Blood 2003, 102:1499-1505.
33. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y: Activated
protein C improves the visceral microcirculation by attenuating the
leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit
Care Med 2005, 33:368-372.
34. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, Decoster B,
Zerimech F, Neviere R: Endothelial glycocalyx damage during
endotoxemia coincides with microcirculatory dysfunction and vascular
oxidative stress. Shock 2008, 29:572-576.
35. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ,
Swanson BA, Jones BE, Grinnell BW: Distinct functions of activated protein
C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009,
20:267-277.
36. Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV:
Endothelial protein C receptor-assisted transport of activated protein C
across the mouse blood-brain barrier. J Cereb Blood Flow Metab 2009,
29:25-33.
Maybauer et al. Critical Care 2010, 14:R217
http://ccforum.com/content/14/6/R217
Page 11 of 1237. Fernandez JA, Xu X, Liu D, Zlokovic BV, Griffin JH: Recombinant murine-
activated protein C is neuroprotective in a murine ischemic stroke
model. Blood Cells Mol Dis 2003, 30:271-276.
38. Lin XJ, Li YL, Mei GP, Zou F, He DD, Liu XQ, Li YJ, Zhao TB, Lin MT:
Activated protein C can be used as a prophylactic as well as a
therapeutic agent for heat stroke in rodents. Shock 2009, 32:524-529.
39. Hauser B, Barth E, Bassi G, Simon F, Groger M, Oter S, Speit G, Ploner F,
Moller P, Wachter U, Vogt JA, Matejovic M, Calzia E, Georgieff M,
Radermacher P, Maybauer DM: Hemodynamic, metabolic, and organ
function effects of pure oxygen ventilation during established fecal
peritonitis-induced septic shock. Crit Care Med 2009, 37:2465-2469.
40. Barth E, Bassi G, Maybauer DM, Simon F, Groger M, Oter S, Speit G,
Nguyen CD, Hasel C, Moller P, Wachter U, Vogt JA, Matejovic M,
Radermacher P, Calzia E: Effects of ventilation with 100% oxygen during
early hyperdynamic porcine fecal peritonitis. Crit Care Med 2008,
36:495-503.
doi:10.1186/cc9342
Cite this article as: Maybauer et al.: Recombinant human activated
protein C attenuates cardiovascular and microcirculatory dysfunction in
acute lung injury and septic shock. Critical Care 2010 14:R217.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maybauer et al. Critical Care 2010, 14:R217
http://ccforum.com/content/14/6/R217
Page 12 of 12